Enterosys, the expert CRO on the gut and gut-brain axis
For more than 2000 years, science and medicine have demonstrated that the root cause of almost all diseases lies in the gut through its interactions with the other organs. The enteric nervous system, called the second brain, together with the gut microbiota and gut hormones play a determining role in these mechanisms. This holistic approach, which takes into account inter-organ communication, is also the foundation of traditional Chinese medicine. In the era of personalized medicine, we believe this new paradigm is opening the way for the development of innovative molecules to treat diseases and prevent health disorders.
Our mission at Enterosys is to provide you with innovative preclinical solutions and models of the digestive system to position and valorize your molecules.
Thanks to the scientific and academic expertise of our founders, we are able to provide top-grade models of the digestive sphere and its modes of communication with peripheral organs.
“Every disease begins in the intestines.”
Hippocrate, the father of modern medicine
ENTEROSYS team :
Academic excellence in Preclinical studies
Dr. Anne Abot
After a PhD in physiology at the University Paul Sabatier in Toulouse (France), in the field of metabolic and cardiovascular diseases, she worked more than ten years in academic research, especially with Pr. Knauf and developed a strong expertise in gut-brain axis and associated pathologies, especially type 2 diabetes. With a master’s degree in innovation management from the Toulouse School of Management, she contributes to the improvement of healthcare solutions by accompanying industries in their innovation process around the digestive sphere and inter-organ communication. She is author/co-author of 28 scientific research publications and reviews.
Her motto is: “The impossible is what takes a little longer”
Pr. Claude Knauf
Pr. Claude Knauf is professor at the University Paul Sabatier in Toulouse (France) and researcher at the INSERM Laboratory (INSERM U1220) in the Digestive Health Research Institute. He is the co-director with Pr. Patrice D. Cani of the European Associated Laboratory “NeuroMicrobiota” involved in the field of metabolic diseases and the importance of microbiota and gut-brain axis in the control of glycemia. Pr. Knauf is member of the French Society of Nutrition (SFN) and of the French Society of Diabetes (SFD). Pr. Knauf is also director of the Master “Microbiote, Metabolism and Nutrition” at the University Paul Sabatier.
His motto: “gut feelings, healthy brain”
Pr Patrice Cani
Patrice D. Cani is senior researcher from FRS-FNRS, group leader at the Louvain Drug Research Institute, Université Catholique de Louvain, Brussels, Belgium. Dr. Cani is recipient of prestigious grants such as WELBIO investigator, ERC Starting Grant 2013 (ENIGMO), PoC ERC grant 2016, the prize “Baillet Latour Grant for Medical Research 2015” and the International Prize of Physiology Lucien Dautrebande (2016). He is member of several international associations and of the Royal Academy of Medicine of Belgium. He is author/co-author of > 200 scientific research publications (h-index: 63; citations >16400; Sept 2017), and also co-founder and director of A-Mansia Biotech SA.
His motto: “In gut, we trust”
Pr. Rémy Burcelin
Research director at the Institute for cardiometabolic research of « Institut National de la Santé et de la Recherche Médicale : INSERM » at Toulouse. Pr R. Burcelin pioneered the discovery of the molecular molecular mechanisms of enteric glucose sensing, notably the role of GLP1 and Glucose transporters, leading to the control of the gut brain axis and of the corresponding physiological functions involved in the glycemic control. He proposed the first molecular mechanisms i.e. the lipopolysaccharides through which the gut microbiota controls metabolism. Altogether, expert in the field of metabolic disease and in the control of metabolic and cardiovascular function by intestinal factors.
His motto: “Make the intestine great again”
Nicolas is an assistant engineer since 2020. After a first experience in the company during a six-month internship, he validated a professional degree at the IUT of Montpellier. He completed a one-year internship in a company specialized in cell culture before coming back to Enterosys.
His motto: “The science of today is the technology of tomorrow”
Dr. Gwendoline Astre
She obtained a PhD at Paul Sabatier University in Toulouse focusing on adipose tissue metabolism and its age-associated pathologies specifically type 2 diabetes. Then, she dug further into the global aged metabolism using the shortest-lived vertebrate in which she elaborated several in vitro and in vivo models and explored different metabolic and inflammatory aspects of aging. She is presently developing new in vitro and ex/in vivo models to implement service offers of Enterosys.
Her motto is: « If you want to go fast, go alone. If you want to go far, go together ».
Business management team
An entrepreneur with a Master’s degree in Business Management from the University of Paris Dauphine and a Bachelor’s degree in Economics. He had a long international experience in multinational companies such as Unilever (18 years) and Shiseido (4 years) before joining SME as CEO. In 2010, he became chairman and CEO of Phythea, a French nutraceutical leader specializing in joint and women’s health. In 2018, he raised €25 million to fund the development of A-Mansia, including €18 million in a Series A round. In December 2021, he decided to join ENTEROSYS as CEO.
His motto: “Gut is the link”
Pauline is our Scientific Business Developer. Its aim is to publicize Enterosys’ service offerings. She obtained a Master’s degree in Health Biology and a Specialized Mastere in Marketing and Sales also in the field of Health. Before joining Enterosys, she worked in a health communication agency. She also worked in the pharmaceutical industry.
Her motto is : « The gut is the key »
Thomas Ehlinger is part of the original founding group and has been President of Enterosys since November 2021. With a dual background in engineering and business, Thomas has worked in entrepreneurship, strategic consulting and private equity as well as in many countries and industries. This multi-faceted experience allows him to work closely with the operational team on two main
areas. The first is to ensure that Enterosys has the appropriate resources to enable its long-term development. The second is to ensure that investments are correctly sized and targeted so that Enterosys’ offering can effectively contribute to the success of its clients. A lover of challenges, an entrepreneur and a passionate innovator, Thomas is now putting his expertise in strategy and organisation at the service of Enterosys’ project: to become the reference preclinical CRO in the field of the gut and the gut-brain axis by making the most of its exceptional human and scientific potential.
His motto: “The sky’s the limit”
Our values: Passion, creativity, responsiveness, rigor, depth and precision.
Enterosys passionately defends the scientific paradigm according to which the gut plays a central role in maintaining the body in good health throughout life. The international scientific and academic excellence of our founders in this field allow us to offer innovative preclinical efficacy testing. The team’s expertise is materialized by the rigor, precision, and scientific depth of the data analysis and the resulting high-quality results. These requirements facilitate the valorization of your molecules. Our scientific creativity and our responsiveness allow us to adapt to your needs and to offer you personalized and differentiating solutions. Finally, thanks to our innovative management approach, we are committed to continuously develop original and innovative models, both in vitro and in vivo.
Our values: Passion, creativity, reactivity, rigor, deepness and precision.
With passion we defend the scientific paradigm of the gut central role in maintaining the body in good health throughout life. The international scientific and academic excellence of our founders in this field allows us to propose innovative preclinical efficacy testing. The team’s expertise is materialized by the rigor, the precision, the scientific deepness of the data analysis and as a result by the quality of the results restitution. This highly demanding facilitates the valorization of your molecules. Our scientific creativity and our reactivity allow us to adapt to your needs in offering you personalized and differentiating solutions. Finally, thanks to our innovation management approach, we are committed to continuously develop new original and innovative models, from in vitro to in vivo.
publications on the subject of the gut and gut-organ axis
of recurrent customers
funded R&D projects
Deontology and ethical approach of our CRO
All our in vivo protocols are approved by the national ethics committee, and are conducted in strict accordance with the 3Rs rule (Replace, Reduce, Refine), under the official supervision of a veterinarian and an animal welfare committee. We design optimized protocols to limit the number of animals included in our studies. To take it even further and limit the use of animal experimentation, we develop innovative physiological models and alternative methods, as close to reality as possible.
Our advanced technological offer
Our experience in R&D and our innovative management approach allow us to provide support in the design and development of new models in order to meet your objectives.
Discover our service offer to accelerate the development of your compounds in preclinical trials.
Our advanced technological offer
Our experience in R&D allows us to meet your objectives and offer you support for the design and development of new models, guided by our innovation management approach.
Discover our service offer to accelerate the development of your compounds in preclinical.
Do you have a question about the contribution of gut models to your preclinical studies and innovation portfolio ?
Our team of experts will be delighted to answer all of your questions. We guide you in the design of an optimized protocol to meet your objectives and add value to your molecules with quick and concrete solutions.